Clinical Trial Update: Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver [NA]

View source ↗

Summary

A Massachusetts General Hospital-sponsored trial is evaluating the immune response to percutaneous hepatic perfusion with melphalan for liver metastases from uv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Uveal Melanoma | NA | Status: RECRUITING